Description

Primobolan 150 – Methenolone Enanthate (Royal Pharmaceuticals)

Catégorie : Injectable Anabolic-Androgenic Steroid (Research Only)
Marque : Royal Pharmaceuticals
Strength: 150 mg methenolone enanthate per ml
Packaging: 10 × 1 ml ampoules (oil-based I.M. solution)
Origin: United Kingdom
Prix : €69
Use Notice: Research/analytical use only — not for human or veterinary administration.

🧪 What is Methenolone Enanthate?

Methenolone enanthate (Primobolan) is a dihydrotestosterone (DHT)-derived anabolic steroid characterised by:

Negligible aromatisation — does not convert to estrogen
Lower androgenic index compared with testosterone
Long-acting enanthate ester that extends release after I.M. injection
Stable anabolic profile often evaluated in nitrogen-balance and lean-mass preservation models

In research contexts, methenolone is studied for its potential to preserve muscle mass, reduce catabolism and support erythropoiesis with fewer estrogen-mediated variables.

🔬 Key Compound Details

Chemical name: 1-methyl-5α-androst-1-en-17β-ol-3-one enanthate
Parent structure: DHT (non-aromatising)
Pharmacological class: Esterified anabolic-androgenic steroid
Route: Intramuscular depot
Androgenic activity: Lower than testosterone in scaled comparisons
Ester effect: Several-day release profile; prolonged exposure window

🧬 Mechanism of Action

After injection, the enanthate ester is slowly cleaved, releasing free methenolone which:

Binds androgen receptors (AR) in skeletal muscle and other tissues
Modulates transcription of androgen-responsive genes
Promotes structural protein synthesis and nitrogen retention
Shows reduced catabolic signalling in some research models
Does not increase estrogenic activity, avoiding aromatase-mediated effects

These characteristics make methenolone valuable for experiments where stable anabolic action is required without confounding estrogenic variables.

📚 Research Highlights & Observations

Lean mass preservation in catabolic states when nutrition is adequate
Mild erythropoietic effect — increases RBC and hemoglobin in some studies
Lower fluid retention compared with aromatising androgens
Relatively favourable tolerability profile in historical clinical literature

These findings apply to controlled laboratory or clinical research settings only.

⚠️ Safety Profile & Possible Adverse Effects

(Based on class-wide AAS research data.)

Androgenic

Acne, oily skin, increased body/facial hair
Potential DHT-related scalp hair loss
Virilisation in females (voice deepening, menstrual disruption)

Cardiovascular & Metabolic

Reduced HDL, possible increase in LDL
Blood pressure changes
Elevated hematocrit via RBC stimulation

Endocrine

Suppression of LH/FSH
Reduced endogenous testosterone
Impaired spermatogenesis and fertility

Hepatic

Lower hepatotoxicity than 17α-alkylated orals, but liver enzymes may still elevate

Other

Injection-site irritation
Mood or behavioural changes
Potential interactions with anticoagulants or metabolic drugs

🛑 Compliance & Regulatory Notice

Methenolone and its esters are prohibited anabolic agents under WADA (S1).
Controlled substance in many jurisdictions; distribution/use may require licensing.
This product is sold strictly for laboratory and analytical research only.
No medical claims, dosing guidance or human-use recommendations are provided.

📊 Technical Data Table

Parameter	Information
Active compound	Methenolone Enanthate
Marque	Royal Pharmaceuticals
Formulation	Sterile oil solution for intramuscular use
Strength	150 mg/ml
Volume per ampoule	1 ml
Total per pack	10 × 1 ml ampoules
Chemical class	DHT-derived anabolic steroid (AAS)
Ester	Enanthate (heptanoate)
Aromatisation	Negligible (non-aromatising)
WADA status	Prohibited at all times (S1 Anabolic Agents)
Primary clearance	Hepatic metabolism; renal/biliary excretion